Alecensa
E821687
anaplastic lymphoma kinase inhibitor
pharmaceutical drug
protein kinase inhibitor
targeted cancer therapy
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
anaplastic lymphoma kinase inhibitor
ⓘ
pharmaceutical drug ⓘ protein kinase inhibitor ⓘ targeted cancer therapy ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
Japanese Pharmaceuticals and Medical Devices Agency NERFINISHED ⓘ U.S. Food and Drug Administration NERFINISHED ⓘ |
| canCross | blood–brain barrier ⓘ |
| developedBy | Chugai Pharmaceutical NERFINISHED ⓘ |
| dosageForm | capsule ⓘ |
| hasActiveIngredient | alectinib ⓘ |
| hasAdministrationSchedule | twice daily dosing ⓘ |
| hasAdverseEffect |
anemia
ⓘ
constipation ⓘ edema ⓘ fatigue ⓘ |
| hasATCCode | L01ED04 ⓘ |
| hasBlackBoxWarning | hepatotoxicity ⓘ |
| hasChemicalFormula | C30H34N4O2 ⓘ |
| hasClinicalTrial |
ALEX trial
NERFINISHED
ⓘ
J-ALEX trial NERFINISHED ⓘ |
| hasDrugClass |
ALK inhibitor
ⓘ
tyrosine kinase inhibitor ⓘ |
| hasHalfLife | about 33 hours ⓘ |
| hasInternationalNonproprietaryName | alectinib ⓘ |
| hasMechanismOfAction |
inhibition of ALK phosphorylation
ⓘ
inhibition of downstream ALK signaling pathways ⓘ |
| hasTradeName | Alecensa NERFINISHED ⓘ |
| hasWarning |
bradycardia
ⓘ
interstitial lung disease ⓘ myalgia ⓘ pneumonitis ⓘ |
| indicatedFor |
first-line treatment of ALK-positive metastatic NSCLC
ⓘ
treatment of ALK-positive metastatic NSCLC after crizotinib ⓘ |
| isPrescriptionDrug | true ⓘ |
| legalStatusEU | prescription only ⓘ |
| legalStatusUS | prescription only ⓘ |
| marketedBy |
F. Hoffmann-La Roche
NERFINISHED
ⓘ
Genentech NERFINISHED ⓘ |
| metabolism | CYP3A4 ⓘ |
| pregnancyCategory | may cause fetal harm ⓘ |
| routeOfAdministration | oral ⓘ |
| targets |
ALK fusion proteins
NERFINISHED
ⓘ
anaplastic lymphoma kinase NERFINISHED ⓘ |
| treats |
ALK-positive NSCLC with brain metastases
ⓘ
ALK-positive non-small cell lung cancer ⓘ metastatic ALK-positive non-small cell lung cancer ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.